Professor Bissan Al-Lazikani
Professor Bissan Al-Lazikani's research focused on developing and applying multidisciplinary computational techniques for drug discovery and clinical application. She was also Head of Data Science at the ICR, where she led the Knowledge Hub Big Data Team for intelligent application of computers in adaptive, individualized therapy. She left the ICR in 2021. 0000-0003-3367-2519
Professor Bissan Al-Lazikani is formally trained in molecular biology and computing. She obtained a BSc (Hons) in molecular biology from University College London, followed by a Masters degree in Computer Science from Imperial College London.
She obtained her PhD in computational structural biology from University of Cambridge and the Medical Research Council Laboratories of Molecular Biology under the supervision of Dr Cyrus Chothia, where she worked on understanding the structural basis for immune recognition. Subsequently, she became a Howard Hughes postdoctoral fellow at the laboratories of Professor Barry Honig in Columbia University, New York, where she focused on structure analysis, prediction and modeling for the purpose of understanding the basis of ligand-receptor interactions.
See all news stories on our website that feature the work of Professor Al-Lazikani and colleagues.
Upon completion of her postdoctoral, Professor Al-Lazikani joined a London-based Biotechnology company, Inpharmatica, where she led a team to develop Chemogenomics databases and tools to aid target prioritisation and drug discovery. These are now available to the community via a Wellcome strategic award through the ChEMBL resources at the European Bioinformatics Institute (EBI).
She joined the Cancer Research UK Cancer Therapeutics Unit (CRUK-CTU) in 2009 to establish and lead the Computational Biology and Chemogenomics Team in order to innovate and apply computational techniques to cancer drug discovery. Here, she the led the development of the world's largest cancer knowledgebase, canSAR, and led the development of novel approaches for objective and systematic evaluation of therapeutic targets for cancer. She applied these approaches for target selection to support drug discovery efforts at the CRUK-CTU and to drive the Unit's exploratory portfolio.
Passionate about the application of Big Data and machine learning to fight cancer, Professor Al-Lazikani then led the Knowledge Hub Big Data initiative to capture and analyse big clinical and preclinical data to enable data-driven adaptive therapy. She was appointed Head of Data Science at the ICR to help deliver the joint ICR and The Royal Marsden NHS Foundation Trust research strategy. She left the ICR in 2021.
When not immersed in Big Data for cancer, she is training for her private pilot's licence and hopes to fly a seaplane one day. She also enjoys astrophotography and wildlife photography with her husband and son.
 Professional activities  Publications  Resources
canSAR resource
canSAR brings together biological, chemical, pharmacological and disease data, distills them and makes them accessible to cancer research scientists from all disciplines to support translational research and drug discovery.
Link out to canSAR
Study polypharmacology earlier in drug discovery, say researchers
New version of canSAR database is more user-friendly, with more data than ever before
See all news
Related blogs
Thinking Inside the Box: five ways the ICR is leading the way with Big Data in cancer research
Three ways global links help our researchers carry out life-changing research on World Cancer Research Day
Related videos
Dr James Campbell on using genomics to improve radiotherapy
See all videos
AKT inhibitors: a new type of targeted cancer drug
canSAR: The AI 'knowledgebase' revolutionising cancer drug discovery
ICR research highlights
Long-term benefit of radiotherapy confirmed in advanced prostate cancer
Immunotherapy drug combination stimulates immune system against resistant cancers
See more